Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Int J Cardiol ; 152(3): 327-31, 2011 Nov 03.
Article in English | MEDLINE | ID: mdl-20797803

ABSTRACT

BACKGROUND: Sulfonylureas have been linked to an increased cardiovascular risk by inhibition of myocardial preconditioning. Whether individual sulfonylureas affect outcomes in diabetic patients after emergent percutaneous coronary intervention for myocardial infarction is unknown. METHODS: All Danish patients receiving glucose-lowering drugs admitted with myocardial infarction between 1997 and 2006 who underwent emergent percutaneous coronary intervention were identified from national registers. Multivariable Cox proportional hazards models were used to analyze the risk of cardiovascular mortality and morbidity associated with sulfonylureas. RESULTS: A total of 926 patients were included and 163 (17.6%) patients died during the first year of which 155 (16.7%) were cardiovascular deaths. The most common treatment was sulfonylureas which were received by 271 (29.3%) patients, and 129 (13.9%) received metformin. Cox proportional hazard regression analyses adjusted for age, sex, calendar year, comorbidity and concomitant pharmacotherapy showed an increased risk of cardiovascular mortality (hazard ratio [HR] 2.91, 95% confidence interval [CI] 1.26-6.72 ; p=0.012), cardiovascular mortality and nonfatal myocardial infarction (HR 2.69 , 95% CI 1.21-6.00; p=0.016), and all-cause mortality (HR 2.46, 95% CI 1.11-5.47; p=0.027), respectively, with glyburide compared to metformin. CONCLUSIONS: Glyburide is associated with increased cardiovascular mortality and morbidity in patients with diabetes mellitus undergoing emergent percutaneous coronary intervention after myocardial infarction. Early reperfusion therapy is the mainstay in modern treatment of myocardial infarction and the time may have come to discard glyburide in favour of sulfonylureas that do not appear to confer increased cardiovascular risk.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Diabetes Mellitus/epidemiology , Glyburide/adverse effects , Myocardial Infarction/epidemiology , Myocardial Infarction/therapy , Registries , Aged , Aged, 80 and over , Denmark/epidemiology , Diabetes Mellitus/drug therapy , Female , Humans , Male , Middle Aged , Myocardial Infarction/drug therapy , Risk Factors , Treatment Outcome
2.
Diabetologia ; 53(8): 1612-9, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20454950

ABSTRACT

AIMS/HYPOTHESIS: We assessed secular trends of cardiovascular outcomes following first diagnosis of myocardial infarction (MI) or diabetes in an unselected population. METHODS: All Danish residents aged > or = 30 years without prior diabetes or MI were identified by individual-level linkage of nationwide registers. Individuals hospitalised with MI or claiming a first-time prescription for a glucose-lowering medication (GLM) during the period from 1997 to 2006 were included. Analyses were by Poisson regression models. Primary endpoints were death by all causes, cardiovascular death and MI. RESULTS: The study included 3,092,580 individuals, of whom 77,147 had incident MI and 118,247 new-onset diabetes. MI patients had an increased short-term risk of all endpoints compared with the general population. The rate ratio (RR) for cardiovascular death within the first year after MI was 11.1 (95% CI 10.8-11.5) in men and 14.8 (14.3-15.3) in women, respectively. The risk rapidly declined and 1 year after the index MI, RR was 2.11 (2.00-2.23) and 2.8 (2.64-2.97) in men and women, respectively. Patients with diabetes carried a constantly elevated risk of all endpoints compared with the general population. The cardiovascular death RR was 1.90 (1.77-2.04) and 1.92 (1.78-2.07) in men and women, respectively during the first year after GLM initiation. CONCLUSIONS/INTERPRETATION: Incident MI is associated with high short-term risk, which decreases rapidly over time. Incident diabetes is associated with a persistent excessive cardiovascular risk after initiation of GLM therapy. This further strengthens the necessity of early multi-factorial intervention in diabetes patients for long-term benefit.


Subject(s)
Diabetes Mellitus, Type 2/mortality , Myocardial Infarction/mortality , Adult , Aged , Aged, 80 and over , Denmark/epidemiology , Diabetes Mellitus, Type 2/diagnosis , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Myocardial Infarction/diagnosis , Registries , Risk , Risk Factors , Time Factors
3.
Harefuah ; 131(9): 307-9, 375, 1996 Nov 01.
Article in Hebrew | MEDLINE | ID: mdl-8981797

ABSTRACT

Fracture of the humeral shaft as a complication of total shoulder replacement or shoulder hemiarthroplasty is infrequent, but has serious consequences. Traumatic injury is the most common reason for humeral fracture. The prosthesis causes corticolysis as a result of aseptic and septic loosening. Concomitant with increasing use of total and hemiarthroplasty of the shoulder, is an increase in aseptic loosening of the prosthesis. This increases the frequency of humeral fracture after the procedures. We reviewed the results of 3 patients, women aged 54 and 68 years, respectively, and a man of 65, who were treated for humeral fracture as a complication of hemiarthroplasty of the shoulder. We recommend surgical treatment for fracture around the tip of the prosthesis. Humeral fracture below the tip of the prosthesis should be treated individually, depending on the surgeon's experience.


Subject(s)
Humeral Fractures/etiology , Humeral Fractures/surgery , Joint Prosthesis/adverse effects , Shoulder Joint/surgery , Aged , Female , Humans , Male , Middle Aged , Prosthesis Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...